Genzyme Corp. buy Riccardo
Zusammenfassung
Diese Einschätzung wurde am 13.03.09 mit einem Endkurs von 40,46 € beendet. Abwärts ging es seit Start der Einschätzung mit Genzyme Corp.. Verglichen mit dem Start ergibt sich eine Rendite von -25,76 %. Riccardo hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Genzyme Corp. | - | - | - | - |
| iShares Core DAX® | -0,92 % | -1,99 % | 13,40 % | 16,08 % |
| iShares Nasdaq 100 | 0,37 % | -0,87 % | 41,54 % | 46,94 % |
| iShares Nikkei 225® | 2,22 % | -5,19 % | 20,50 % | 4,64 % |
| iShares S&P 500 | -0,03 % | -0,92 % | 30,41 % | 42,42 % |
Kommentare von Riccardo zu dieser Einschätzung
In der Diskussion Genzyme Corp. diskutieren
Kaufenswert
Genzyme Corporation operates as a biotechnology company worldwide. It operates through five segments: Renal, Therapeutics, Transplant, Biosurgery, and Genetics. The Renal segment develops, manufactures, and distributes products for patients suffering from renal diseases, including chronic renal failure. This segment offers Renagel, a phosphate binder for the control of serum phosphorus in patients with chronic kidney disease (CKD) on hemodialysis; and Hectorol vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism in patients with stages 3 and 4 CKD, and in patients with stage 5 CKD on dialysis. The Therapeutics segment provides Cerezyme/Ceredase, an enzyme replacement therapy for the treatment of Gaucher disease; Fabrazyme, a recombinant form of the human enzyme alpha-galactosidase for the treatment of Fabry disease; Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with thyroid cancer; Myozyme therapy for Pompe disease; and Aldurazyme, a recombinant form of the human enzyme alpha-L-iduronidase to treat mucopolysaccharidosis I. The Transplant segment offers Thymoglobulin, a polyclonal antibody that suppresses immune cells responsible for acute organ rejection in transplant patients. The Biosurgery segment markets Synvisc, a biomaterial used to treat the pain associated with osteoarthritis of the knee; and Sepra products for preventing adhesions following various surgical procedures in the body. The Genetics segment provides reproductive testing services, diagnostic services for reproductive and oncology markets, and genetic counseling services. It has a collaboration agreement with PTC Therapeutics, Inc. to develop and commercialize PTC124 for the treatment of genetic disorders due to nonsense mutations. The company was founded in 1981 and is based in Cambridge, Massachusetts.